https://www.selleckchem.com/pr....oducts/Vorinostat-sa
001). For specific aspects of treatment, ravulizumab was preferred (in comparison to no preference or eculizumab) on infusion frequency (98% vs. 0% vs. 2%), ability to plan activities (98% vs. 0% vs. 2%), and overall quality of life (88% vs. 11% vs. 1%), among other aspects. Most participants selected frequency of infusions as the most important factor determining preference (43%), followed by overall quality of life (23%). This study shows that a substantial proportion of patients preferred ravulizumab over eculizumab and provi
Like
Comment
Share
